Stephens Inc’s GSK GSK Stock Holding History

Stephens Inc’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.87M	Sell	33,836 -8,990	-21%	-$487K	0.02%	482
2025 Q4	$2.1M	Sell	42,826 -2,965	-6%	-$138K	0.03%	469
2025 Q3	$1.98M	Sell	45,791 -182	-0.4%	-$7.11K	0.03%	487
2025 Q2	$1.77M	Buy	45,973 +5,403	+13%	+$206K	0.02%	498
2025 Q1	$1.57M	Buy	40,570 +3,638	+10%	+$133K	0.02%	524
2024 Q4	$1.25M	Buy	36,932 +3,472	+10%	+$125K	0.02%	548
2024 Q3	$1.37M	Sell	33,460 -1,139	-3%	-$46.6K	0.02%	527
2024 Q2	$1.33M	Sell	34,599 -689	-2%	-$29K	0.02%	515
2024 Q1	$1.51M	Sell	35,288 -56	-0.2%	-$2.31K	0.02%	478
2023 Q4	$1.31M	Sell	35,344 -6,795	-16%	-$244K	0.02%	480
2023 Q3	$1.53M	Buy	42,139 +1,251	+3%	+$44.4K	0.03%	436
2023 Q2	$1.46M	Sell	40,888 -1,325	-3%	-$47.5K	0.03%	455
2023 Q1	$1.5M	Buy	42,213 +5,932	+16%	+$208K	0.03%	452
2022 Q4	$1.27M	Buy	36,281 +2,291	+7%	+$76.3K	0.03%	464
2022 Q3	$1M	Sell	33,990 -4,164	-11%	-$158K	0.02%	518
2022 Q2	$2.08M	Sell	38,154 -4,044	-10%	-$223K	0.04%	370
2022 Q1	$2.3M	Sell	42,198 -6,425	-13%	-$349K	0.04%	398
2021 Q4	$2.68M	Sell	48,623 -31,899	-40%	-$1.66M	0.04%	391
2021 Q3	$3.85M	Sell	80,522 -9,228	-10%	-$464K	0.06%	328
2021 Q2	$4.47M	Sell	89,750 -2,446	-3%	-$118K	0.07%	296
2021 Q1	$4.11M	Buy	92,196 +7,294	+9%	+$331K	0.07%	290
2020 Q4	$3.9M	Sell	84,902 -41,235	-33%	-$1.89M	0.07%	277
2020 Q3	$5.93M	Sell	126,137 -14,097	-10%	-$706K	0.12%	171
2020 Q2	$7.15M	Sell	140,234 -11,734	-8%	-$602K	0.15%	144
2020 Q1	$7.2M	Sell	151,968 -73,327	-33%	-$3.91M	0.19%	123
2019 Q4	$13.2M	Sell	225,295 -1,781	-0.8%	-$99.1K	0.28%	87
2019 Q3	$12.1M	Sell	227,076 -2,065	-0.9%	-$106K	0.27%	91
2019 Q2	$11.5M	Buy	229,141 +2,594	+1%	+$130K	0.26%	93
2019 Q1	$11.8M	Buy	226,547 +14,549	+7%	+$727K	0.28%	87
2018 Q4	$10.1M	Sell	211,998 -3,240	-2%	-$160K	0.29%	82
2018 Q3	$10.8M	Sell	215,238 -13,320	-6%	-$677K	0.27%	87
2018 Q2	$11.5M	Sell	228,558 -36,381	-14%	-$1.83M	0.35%	66
2018 Q1	$12.9M	Buy	264,939 +94,048	+55%	+$4.38M	0.48%	45
2017 Q4	$7.58M	Sell	170,891 -132,366	-44%	-$6.11M	0.28%	87
2017 Q3	$15.4M	Buy	303,257 +27,633	+10%	+$1.4M	0.56%	33
2017 Q2	$14.9M	Buy	275,624 +21,365	+8%	+$1.14M	0.51%	35
2017 Q1	$13.4M	Buy	254,259 +19,200	+8%	+$974K	0.49%	37
2016 Q4	$11.3M	Sell	235,059 -34,762	-13%	-$1.72M	0.46%	40
2016 Q3	$14.5M	Sell	269,821 -19,635	-7%	-$1.08M	0.64%	26
2016 Q2	$15.7M	Buy	289,456 +23,255	+9%	+$1.23M	0.7%	21
2016 Q1	$13.5M	Buy	266,201 +22,846	+9%	+$1.14M	0.66%	24
2015 Q4	$12.3M	Buy	243,355 +19,029	+8%	+$970K	0.62%	28
2015 Q3	$10.8M	Buy	224,326 +6,050	+3%	+$315K	0.56%	28
2015 Q2	$11.4M	Buy	218,276 +13,158	+6%	+$741K	0.52%	29
2015 Q1	$11.8M	Buy	205,118 +11,286	+6%	+$647K	0.54%	27
2014 Q4	$10.4M	Buy	193,832 +25,032	+15%	+$1.4M	0.49%	32
2014 Q3	$9.7M	Buy	168,800 +73,319	+77%	+$4.49M	0.48%	31
2014 Q2	$6.38M	Buy	95,481 +17,284	+22%	+$1.17M	0.32%	53
2014 Q1	$5.22M	Buy	78,197 +6,919	+10%	+$468K	0.28%	70
2013 Q4	$4.76M	Buy	71,278 +465	+0.7%	+$30.2K	0.24%	75
2013 Q3	$4.44M	Sell	70,813 -10,161	-13%	-$654K	0.24%	75
2013 Q2	$5.06M	Buy	+80,974	New	+$5.14M	0.28%	61

Other funds holding GSK

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Stephens Inc's GSK Position: Q1 2026 in Review

Stephens Inc reduced its GSK (GSK) stake by 21% in Q1 2026, selling an estimated $487K and leaving 33,836 shares worth $1.87M. The position accounts for 0.02% of the portfolio, ranked #482.

Stephens Inc first reported a position in GSK in Q2 2013 and has held it in 52 quarters since. The position peaked at $15.7M in Q2 2016. 1,031 funds tracked by Wall St. Rank hold GSK as of Q1 2026.

Stephens Inc held 33,836 shares of GSK worth $1.87M as of Q1 2026.
Stephens Inc sold 8,990 GSK shares in Q1 2026, an estimated $487K.
GSK made up 0.02% of Stephens Inc's portfolio in Q1 2026, its #482 holding.
Stephens Inc first reported a position in GSK in Q2 2013 and has held it in 52 quarters since.
Stephens Inc's GSK position peaked at $15.7M in Q2 2016.
1,031 funds tracked by Wall St. Rank held GSK as of Q1 2026.

Based on Stephens Inc's 13F filing for Q1 2026, filed 28 Apr 2026.